<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37208030</PMID><DateCompleted><Year>2023</Year><Month>05</Month><Day>22</Day></DateCompleted><DateRevised><Year>2023</Year><Month>06</Month><Day>13</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2056-5933</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><Issue>2</Issue><PubDate><Year>2023</Year><Month>May</Month></PubDate></JournalIssue><Title>RMD open</Title><ISOAbbreviation>RMD Open</ISOAbbreviation></Journal><ArticleTitle>Four trajectories of 24-hour urine protein levels in real-world lupus nephritis cohorts.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">e002930</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1136/rmdopen-2022-002930</ELocationID><Abstract><AbstractText Label="OBJECTIVES">A 24-hour urine protein (24hUP) is a key measurement in the management of lupus nephritis (LN); however, trajectories of 24hUP in LN is poorly defined.</AbstractText><AbstractText Label="METHODS">Two LN cohorts that underwent renal biopsies at Renji Hospital were included. Patients received standard of care in a real-world setting and 24hUP data were collected over time. Trajectory patterns of 24hUP were determined using the latent class mixed modelling (LCMM). Baseline characters were compared among trajectories and multinomial logistic regression was used to determine independent risk factors. Optimal combinations of variables were identified for model construction and user-friendly nomograms were developed.</AbstractText><AbstractText Label="RESULTS">The derivation cohort composed of 194 patients with LN with 1479 study visits and a median follow-up of 17.5 (12.2-21.7) months. Four trajectories of 24hUP were identified, that is, Rapid Responders, Good Responders, Suboptimal Responders and Non-Responders, with the KDIGO renal complete remission rates (time to complete remission, months) of 84.2% (4.19), 79.6% (7.94), 40.4% (not applicable) and 9.8% (not applicable), respectively (p&lt;0.001). The 'Rapid Responders' distinguish itself from other trajectories and a nomogram, composed of age, systemic lupus erythematosus duration, albumin and 24hUP yielded C-indices &gt;0.85. Another nomogram to predict 'Good Responders' yielded C-indices of 0.73~0.78, which composed of gender, new-onset LN, glomerulosclerosis and partial remission within 6 months. When applied to the validation cohort with 117 patients and 500 study visits, nomograms effectively sorted out 'Rapid Responders' and 'Good Responders'.</AbstractText><AbstractText Label="CONCLUSION">Four trajectories of LN shed some light to guide the management of LN and further clinical trials design.</AbstractText><CopyrightInformation>&#xa9; Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Zhang</LastName><ForeName>Danting</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0001-7205-8795</Identifier><AffiliationInfo><Affiliation>Department of Rheumatology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University School of Medicine, 2000 Jiangye Rd, Shanghai, 201112, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Sun</LastName><ForeName>Fangfang</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0003-2570-4576</Identifier><AffiliationInfo><Affiliation>Department of Rheumatology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University School of Medicine, 2000 Jiangye Rd, Shanghai, 201112, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Jie</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-0225-1853</Identifier><AffiliationInfo><Affiliation>Department of Rheumatology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University School of Medicine, 2000 Jiangye Rd, Shanghai, 201112, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ding</LastName><ForeName>Huihua</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Rheumatology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University School of Medicine, 145 Shandong (M) Rd, Shanghai, 200001, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Xiaodong</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Rheumatology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University School of Medicine, 2000 Jiangye Rd, Shanghai, 201112, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Shen</LastName><ForeName>Nan</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0002-5875-4417</Identifier><AffiliationInfo><Affiliation>Department of Rheumatology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University School of Medicine, 145 Shandong (M) Rd, Shanghai, 200001, China nanshensibs@gmail.com leeting007@163.com ye_shuang2000@163.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Li</LastName><ForeName>Ting</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0001-6800-6650</Identifier><AffiliationInfo><Affiliation>Department of Rheumatology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University School of Medicine, 2000 Jiangye Rd, Shanghai, 201112, China nanshensibs@gmail.com leeting007@163.com ye_shuang2000@163.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Ye</LastName><ForeName>Shuang</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-5257-5768</Identifier><AffiliationInfo><Affiliation>Department of Rheumatology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University School of Medicine, 2000 Jiangye Rd, Shanghai, 201112, China nanshensibs@gmail.com leeting007@163.com ye_shuang2000@163.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>RMD Open</MedlineTA><NlmUniqueID>101662038</NlmUniqueID><ISSNLinking>2056-5933</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008181" MajorTopicYN="Y">Lupus Nephritis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007668" MajorTopicYN="N">Kidney</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012074" MajorTopicYN="N">Remission Induction</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Epidemiology</Keyword><Keyword MajorTopicYN="N">Lupus Erythematosus, Systemic</Keyword><Keyword MajorTopicYN="N">Lupus Nephritis</Keyword></KeywordList><CoiStatement>Competing interests: None declared.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>12</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>4</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>5</Month><Day>22</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>5</Month><Day>20</Day><Hour>9</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>5</Month><Day>19</Day><Hour>20</Hour><Minute>52</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37208030</ArticleId><ArticleId IdType="pmc">PMC10201270</ArticleId><ArticleId IdType="doi">10.1136/rmdopen-2022-002930</ArticleId><ArticleId IdType="pii">rmdopen-2022-002930</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Croca SC, Rodrigues T, Isenberg DA. Assessment of a lupus nephritis cohort over a 30-year period. Rheumatology (Oxford) 2011;50:1424&#x2013;30. 10.1093/rheumatology/ker101</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/ker101</ArticleId><ArticleId IdType="pubmed">21415024</ArticleId></ArticleIdList></Reference><Reference><Citation>Maroz N, Segal MS. Lupus nephritis and end-stage kidney disease. Am J Med Sci 2013;346:319&#x2013;23. 10.1097/MAJ.0b013e31827f4ee3</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MAJ.0b013e31827f4ee3</ArticleId><ArticleId IdType="pubmed">23370533</ArticleId></ArticleIdList></Reference><Reference><Citation>Tamirou F, Houssiau FA. Management of lupus nephritis. J Clin Med 2021;10:670. 10.3390/jcm10040670</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm10040670</ArticleId><ArticleId IdType="pmc">PMC7916202</ArticleId><ArticleId IdType="pubmed">33572385</ArticleId></ArticleIdList></Reference><Reference><Citation>Fraenkel L, MacKenzie T, Joseph L, et al. . Response to treatment as a predictor of longterm outcome in patients with lupus nephritis. J Rheumatol 1994;21:2052&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">7869309</ArticleId></ArticleIdList></Reference><Reference><Citation>Houssiau FA, Vasconcelos C, D&#x2019;Cruz D, et al. . Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long-term followup of patients in the euro-lupus nephritis trial. Arthritis Rheum 2004;50:3934&#x2013;40. 10.1002/art.20666</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.20666</ArticleId><ArticleId IdType="pubmed">15593207</ArticleId></ArticleIdList></Reference><Reference><Citation>Houssiau FA, Vasconcelos C, D&#x2019;Cruz D, et al. . The 10-year follow-up data of the euro-lupus nephritis trial comparing low-dose and high-dose intravenous cyclophosphamide. Ann Rheum Dis 2010;69:61&#x2013;4. 10.1136/ard.2008.102533</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ard.2008.102533</ArticleId><ArticleId IdType="pubmed">19155235</ArticleId></ArticleIdList></Reference><Reference><Citation>Korbet SM, Lewis EJ, Collaborative Study Group . Severe lupus nephritis: the predictive value of a &#x2265; 50 % reduction in proteinuria at 6 months. Nephrol Dial Transplant 2013;28:2313&#x2013;8. 10.1093/ndt/gft201</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ndt/gft201</ArticleId><ArticleId IdType="pubmed">23787551</ArticleId></ArticleIdList></Reference><Reference><Citation>Moroni G, Gatto M, Tamborini F, et al. . Lack of EULAR/ERA-EDTA response at 1 year predicts poor long-term renal outcome in patients with lupus nephritis. Ann Rheum Dis 2020;79:1077&#x2013;83. 10.1136/annrheumdis-2020-216965</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2020-216965</ArticleId><ArticleId IdType="pubmed">32503858</ArticleId></ArticleIdList></Reference><Reference><Citation>Dall&#x2019;Era M, Cisternas MG, Smilek DE, et al. . Predictors of long-term renal outcome in lupus nephritis trials: lessons learned from the euro-lupus nephritis cohort. Arthritis &amp; Rheumatology 2015;67:1305&#x2013;13. 10.1002/art.39026</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.39026</ArticleId><ArticleId IdType="pubmed">25605554</ArticleId></ArticleIdList></Reference><Reference><Citation>Tamirou F, Lauwerys BR, Dall&#x2019;Era M, et al. . A proteinuria cut-off level of 0.7 g/day after 12 months of treatment best predicts long-term renal outcome in lupus nephritis: data from the maintain nephritis trial. Lupus Sci Med 2015;2:e000123. 10.1136/lupus-2015-000123</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/lupus-2015-000123</ArticleId><ArticleId IdType="pmc">PMC4654096</ArticleId><ArticleId IdType="pubmed">26629352</ArticleId></ArticleIdList></Reference><Reference><Citation>Fanouriakis A, Kostopoulou M, Cheema K, et al. . 2019 update of the joint European League against rheumatism and European renal association&#x2013;european dialysis and transplant association (EULAR/ERA&#x2013;EDTA) recommendations for the management of lupus nephritis. Ann Rheum Dis 2020;79:713&#x2013;23. 10.1136/annrheumdis-2020-216924</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2020-216924</ArticleId><ArticleId IdType="pubmed">32220834</ArticleId></ArticleIdList></Reference><Reference><Citation>Cattran DC, Feehally J, Cook HT. KDIGO clinical practice guideline for glomerulonephritis. Kidney International Supplements 2012;2:139. 10.1038/kisup.2012.9</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/kisup.2012.9</ArticleId></ArticleIdList></Reference><Reference><Citation>Helget LN, Dillon DJ, Wolf B, et al. . Development of a lupus nephritis suboptimal response prediction tool using renal histopathological and clinical laboratory variables at the time of diagnosis. Lupus Sci Med 2021;8:8.:e000489. 10.1136/lupus-2021-000489</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/lupus-2021-000489</ArticleId><ArticleId IdType="pmc">PMC8386213</ArticleId><ArticleId IdType="pubmed">34429335</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayoub I, Wolf BJ, Geng L, et al. . Prediction models of treatment response in lupus nephritis. Kidney Int 2022;101:379&#x2013;89. 10.1016/j.kint.2021.11.014</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.kint.2021.11.014</ArticleId><ArticleId IdType="pmc">PMC8792241</ArticleId><ArticleId IdType="pubmed">34871620</ArticleId></ArticleIdList></Reference><Reference><Citation>Schirmbeck F, van der Burg NC, Blankers M, et al. . Impact of comorbid affective disorders on longitudinal clinical outcomes in individuals at ultra-high risk for psychosis. Schizophr Bull 2022;48:100&#x2013;10. 10.1093/schbul/sbab088</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/schbul/sbab088</ArticleId><ArticleId IdType="pmc">PMC8781381</ArticleId><ArticleId IdType="pubmed">34417795</ArticleId></ArticleIdList></Reference><Reference><Citation>Michopoulos V, Beurel E, Gould F, et al. . Association of prospective risk for chronic PTSD symptoms with low TNF&#x3b1; and IFN&#x3b3; concentrations in the immediate aftermath of trauma exposure. AJP 2020;177:58&#x2013;65. 10.1176/appi.ajp.2019.19010039</Citation><ArticleIdList><ArticleId IdType="doi">10.1176/appi.ajp.2019.19010039</ArticleId><ArticleId IdType="pubmed">31352811</ArticleId></ArticleIdList></Reference><Reference><Citation>Raynaud M, Aubert O, Reese PP, et al. . Trajectories of glomerular filtration rate and progression to end stage kidney disease after kidney transplantation. Kidney Int 2021;99:186&#x2013;97. 10.1016/j.kint.2020.07.025</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.kint.2020.07.025</ArticleId><ArticleId IdType="pubmed">32781106</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang G, Luk AOY, Tam CHT, et al. . Progression of diabetic kidney disease and trajectory of kidney function decline in Chinese patients with type 2 diabetes. Kidney Int 2019;95:178&#x2013;87. 10.1016/j.kint.2018.08.026</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.kint.2018.08.026</ArticleId><ArticleId IdType="pubmed">30415941</ArticleId></ArticleIdList></Reference><Reference><Citation>Geifman N, Kennedy RE, Schneider LS, et al. . Data-Driven identification of endophenotypes of Alzheimer&#x2019;s disease progression: implications for clinical trials and therapeutic interventions. Alzheimers Res Ther 2018;10:4. 10.1186/s13195-017-0332-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13195-017-0332-0</ArticleId><ArticleId IdType="pmc">PMC6389228</ArticleId><ArticleId IdType="pubmed">29370871</ArticleId></ArticleIdList></Reference><Reference><Citation>Merlo D, Stankovich J, Bai C, et al. . Association between cognitive trajectories and disability progression in patients with relapsing-remitting multiple sclerosis. Neurology 2021;97:e2020&#x2013;31. 10.1212/WNL.0000000000012850</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000012850</ArticleId><ArticleId IdType="pubmed">34556562</ArticleId></ArticleIdList></Reference><Reference><Citation>Platzer A, Alasti F, Smolen JS, et al. . Trajectory clusters of radiographic progression in patients with rheumatoid arthritis: associations with clinical variables. Ann Rheum Dis 2022;81:175&#x2013;83. 10.1136/annrheumdis-2021-220331</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2021-220331</ArticleId><ArticleId IdType="pubmed">34376384</ArticleId></ArticleIdList></Reference><Reference><Citation>Dagliati A, Plant D, Nair N, et al. . Latent class trajectory modeling of 2-component disease activity score in 28 joints identifies multiple rheumatoid arthritis phenotypes of response to biologic disease-modifying antirheumatic drugs. Arthritis Rheumatol 2020;72:1632&#x2013;42. 10.1002/art.41379</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.41379</ArticleId><ArticleId IdType="pubmed">32475078</ArticleId></ArticleIdList></Reference><Reference><Citation>Watson L, Belcher J, Nicholls E, et al. . Latent class growth analysis of gout flare trajectories: a three-year prospective cohort study in primary care. Arthritis Rheumatol 2020;72:1928&#x2013;35. 10.1002/art.41476</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.41476</ArticleId><ArticleId IdType="pubmed">32767502</ArticleId></ArticleIdList></Reference><Reference><Citation>Reynolds JA, Prattley J, Geifman N, et al. . Distinct patterns of disease activity over time in patients with active SLE revealed using latent class trajectory models. Arthritis Res Ther 2021;23:203. 10.1186/s13075-021-02584-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13075-021-02584-x</ArticleId><ArticleId IdType="pmc">PMC8320218</ArticleId><ArticleId IdType="pubmed">34321096</ArticleId></ArticleIdList></Reference><Reference><Citation>Hochberg MC. Updating the American College of rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997;40:1725. 10.1002/art.1780400928</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.1780400928</ArticleId><ArticleId IdType="pubmed">9324032</ArticleId></ArticleIdList></Reference><Reference><Citation>Weeding E, Fava A, Magder L, et al. . One-Third of patients with lupus nephritis classified as complete responders continue to accrue progressive renal damage despite resolution of proteinuria. Lupus Sci Med 2022;9:e000684. 10.1136/lupus-2022-000684</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/lupus-2022-000684</ArticleId><ArticleId IdType="pmc">PMC9047706</ArticleId><ArticleId IdType="pubmed">35512816</ArticleId></ArticleIdList></Reference><Reference><Citation>Fiehn C, Hajjar Y, Mueller K, et al. . Improved clinical outcome of lupus nephritis during the past decade: importance of early diagnosis and treatment. Ann Rheum Dis 2003;62:435&#x2013;9. 10.1136/ard.62.5.435</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ard.62.5.435</ArticleId><ArticleId IdType="pmc">PMC1754523</ArticleId><ArticleId IdType="pubmed">12695156</ArticleId></ArticleIdList></Reference><Reference><Citation>Proust-Lima C, Philipps V, Liquet B. Estimation of extended mixed models using latent classes and latent processes: the R package lcmm. J Stat Softw 2017;78:1&#x2013;56. 10.18637/jss.v078.i02</Citation><ArticleIdList><ArticleId IdType="doi">10.18637/jss.v078.i02</ArticleId></ArticleIdList></Reference><Reference><Citation>Lennon H, Kelly S, Sperrin M, et al. . Framework to construct and interpret latent class trajectory modelling. BMJ Open 2018;8:e020683. 10.1136/bmjopen-2017-020683</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2017-020683</ArticleId><ArticleId IdType="pmc">PMC6042544</ArticleId><ArticleId IdType="pubmed">29982203</ArticleId></ArticleIdList></Reference><Reference><Citation>Weening JJ, D&#x2019;agati VD, Schwartz MM, et al. . The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney International 2004;65:521&#x2013;30. 10.1111/j.1523-1755.2004.00443.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1523-1755.2004.00443.x</ArticleId><ArticleId IdType="pubmed">14717922</ArticleId></ArticleIdList></Reference><Reference><Citation>Furie R, Rovin BH, Houssiau F, et al. . Two-Year, randomized, controlled trial of belimumab in lupus nephritis. N Engl J Med 2020;383:1117&#x2013;28. 10.1056/NEJMoa2001180</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2001180</ArticleId><ArticleId IdType="pubmed">32937045</ArticleId></ArticleIdList></Reference><Reference><Citation>Furie RA, Aroca G, Cascino MD, et al. . B-Cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial. Ann Rheum Dis 2022;81:100&#x2013;7. 10.1136/annrheumdis-2021-220920</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2021-220920</ArticleId><ArticleId IdType="pmc">PMC8762029</ArticleId><ArticleId IdType="pubmed">34615636</ArticleId></ArticleIdList></Reference><Reference><Citation>Rovin BH, Teng YKO, Ginzler EM, et al. . Efficacy and safety of voclosporin versus placebo for lupus nephritis (Aurora 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 2021;397:2070&#x2013;80. 10.1016/S0140-6736(21)00578-X</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)00578-X</ArticleId><ArticleId IdType="pubmed">33971155</ArticleId></ArticleIdList></Reference><Reference><Citation>Rovin BH, Furie R, Latinis K, et al. . Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the lupus nephritis assessment with rituximab study. Arthritis &amp; Rheumatism 2012;64:1215&#x2013;26. 10.1002/art.34359</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.34359</ArticleId><ArticleId IdType="pubmed">22231479</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolf BJ, Spainhour JC, Arthur JM, et al. . Development of biomarker models to predict outcomes in lupus nephritis. Arthritis &amp; Rheumatology 2016;68:1955&#x2013;63. 10.1002/art.39623</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.39623</ArticleId><ArticleId IdType="pmc">PMC5201110</ArticleId><ArticleId IdType="pubmed">26867033</ArticleId></ArticleIdList></Reference><Reference><Citation>McDonald S, Yiu S, Su L, et al. . Predictors of treatment response in a lupus nephritis population: lessons from the aspreva lupus management study (alms) trial. Lupus Sci Med 2022;9:e000584. 10.1136/lupus-2021-000584</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/lupus-2021-000584</ArticleId><ArticleId IdType="pmc">PMC9157342</ArticleId><ArticleId IdType="pubmed">35640982</ArticleId></ArticleIdList></Reference><Reference><Citation>Austin HA, Muenz LR, Joyce KM, et al. . Diffuse proliferative lupus nephritis: identification of specific pathologic features affecting renal outcome. Kidney Int 1984;25:689&#x2013;95. 10.1038/ki.1984.75</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ki.1984.75</ArticleId><ArticleId IdType="pubmed">6482173</ArticleId></ArticleIdList></Reference><Reference><Citation>Rovin BH, Adler SG, Barratt J, et al. . Executive summary of the KDIGO 2021 guideline for the management of glomerular diseases. Kidney International 2021;100:753&#x2013;79. 10.1016/j.kint.2021.05.015</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.kint.2021.05.015</ArticleId><ArticleId IdType="pubmed">34556300</ArticleId></ArticleIdList></Reference><Reference><Citation>Medina JE, Gladman DD, Urowitz MB, et al. . SAT0404 spot urine protein/creatinine ratio is useful in screening for proteinuria but should not substitute 24 hours urine collection sample to quantify proteinuria in lupus. Ann Rheum Dis 2015;74(Suppl 2):805. 10.1136/annrheumdis-2015-eular.4852</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2015-eular.4852</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>